FAQ on Scinai Immunotherapeutics Ltd.'s PC111 Breakthrough and Dr. Roberta Lotti's Award

What is PC111 and its significance in dermatology?

PC111 is a first-in-class anti-Fas Ligand monoclonal antibody that blocks blister formation by preventing keratinocyte apoptosis in pemphigus vulgaris, offering a potential non-immunosuppressive, disease-modifying treatment for severe autoimmune skin conditions.

Who is Dr. Roberta Lotti and what award did she win?

Dr. Roberta Lotti of Pincell Srl won the ‘Oscar of Italian Dermatology’ from SIDeMaST for her research on PC111, highlighting its breakthrough in treating pemphigus vulgaris.

What is Scinai Immunotherapeutics Ltd.’s connection to PC111?

Scinai holds an option to acquire Pincell Srl and is advancing PC111 as a lead asset, emphasizing its potential in treating severe autoimmune skin conditions.

Where can I find more information about Scinai Immunotherapeutics Ltd.?

For more information, visit Scinai’s website at www.Scinai.com or the company’s newsroom at https://ibn.fm/SCNI.

What are the implications of PC111’s breakthrough for patients with pemphigus vulgaris?

PC111’s ability to block blister formation without immunosuppression offers a promising, disease-modifying treatment option for patients suffering from pemphigus vulgaris, a severe autoimmune skin condition.

How does PC111 compare to current treatments for pemphigus vulgaris?

PC111 is highlighted as a non-immunosuppressive, disease-modifying treatment, potentially offering a safer and more effective alternative to current immunosuppressive therapies for pemphigus vulgaris.

What is the title of the study published about PC111?

The study is titled ‘Blocking soluble Fas Ligand ameliorates pemphigus’, confirming PC111’s ability to block blister formation in pemphigus vulgaris.

Where can I view the full press release about PC111 and Dr. Lotti’s award?

The full press release can be viewed at https://ibn.fm/51v14.